Gilead has presented promising Phase II results for its experimental NASH drug GS-0976, showing significant reductions in the build up of liver fat and a marker of fibrosis.
Bristol-Myers Squibb’s investigational liver disease candidate has hit its targets in a mid-stage trial, supporting further research on the drug as a potential treatment for Nonalcoholic Steatohepatitis (NASH).